The Experts below are selected from a list of 51 Experts worldwide ranked by ideXlab platform
D Buell - One of the best experts on this subject based on the ideXlab platform.
-
successful treatment of oesophageal candidiasis by micafungin a novel Systemic Antifungal Agent
Alimentary Pharmacology & Therapeutics, 2004Co-Authors: K Pettengell, J Mynhardt, T Kluyts, D Facklam, D BuellAbstract:Summary Aim : To determine the minimum effective dose and safety of micafungin in the treatment of HIV-related oesophageal candidiasis. Method : A total of 120 patients were enrolled in this open label study of the effects of daily 1 h infusions of micafungin on endoscopically proven fungal oesophagitis. Patients were randomly assigned to receive 12.5, 25, 50, 75 and 100 mg of micafungin daily. Response was evaluated clinically and endoscopically. Results : The protocol defined minimum effective dose of micafungin was 12.5 mg. The percentage of patients experiencing clearing of physical signs and symptoms showed a dose–response relationship and reached 94.7% in the 100 mg dose group. All patients in the 50, 75 and 100 mg dose groups achieved an endoscopically verified improvement in oesophagitis. Adverse effects of micafungin were generally mild and not dose-related. No serious renal, hepatic or drug-related infusion reactions were encountered. Conclusion : Micafungin was found to be effective, well-tolerated and safe. The minimum effective dose was found to be 12.5 mg and a significant linear trend in the successful treatment of oesophageal candidiasis was observed across the doses used with 75 and 100 mg dose levels achieving high rates of clinical and endoscopic cure.
D Facklam - One of the best experts on this subject based on the ideXlab platform.
-
Micafungin (FK463), alone or in combination with other Systemic Antifungal Agents, for the treatment of acute invasive aspergillosis
Journal of Infection, 2006Co-Authors: David W. Denning, D Facklam, Kieren A. Marr, Voravit Ratanatharathorn, Cornelia Becker, Andrew J. Ullmann, Nita L. Seibel, Patricia M. Flynn, Jo Anne H Van BurikAbstract:Summary Background Micafungin (FK463) is a new lipopeptide compound (echinocandin) with activity against Aspergillus and Candida species. This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA). Methods A multinational, non-comparative study was conducted to examine proven or probable (pulmonary only) Aspergillus species infection in a wide variety of patient populations. The study employed an open-label design utilizing micafungin alone or in combination with another Systemic Antifungal Agent. Criteria for IA and therapeutic responses were judged by an independent panel. Results Of the 331 patients enrolled, only 225 met diagnostic criteria for IA as determined by the independent panel and received at least one dose of micafungin. Patients included 98/225 who had undergone hematopoietic stem cell transplantation (HSCT) (88/98 allogeneic), 48 with graft versus host disease (GVHD), and 83/225 who had received chemotherapy for hematologic malignancy. A favorable response rate at the end of therapy was seen in 35.6% (80/225) of patients. Of those only treated with micafungin, favorable responses were seen in 6/12 (50%) of the primary and 9/22 (40.9%) of the salvage therapy group, with corresponding numbers in the combination treatment groups of 5/17 (29.4%) and 60/174 (34.5%) of the primary and salvage treatment groups, respectively. Of the 326 micafungin-treated patients, 183 (56.1%) died during therapy or in the 6-week follow-up phase; 107 (58.5%) deaths were attributable to IA. Conclusions Micafungin as primary or salvage therapy proved efficacious and safe in high-risk patients with IA, although patient numbers are small in the micafungin-only groups.
-
successful treatment of oesophageal candidiasis by micafungin a novel Systemic Antifungal Agent
Alimentary Pharmacology & Therapeutics, 2004Co-Authors: K Pettengell, J Mynhardt, T Kluyts, D Facklam, D BuellAbstract:Summary Aim : To determine the minimum effective dose and safety of micafungin in the treatment of HIV-related oesophageal candidiasis. Method : A total of 120 patients were enrolled in this open label study of the effects of daily 1 h infusions of micafungin on endoscopically proven fungal oesophagitis. Patients were randomly assigned to receive 12.5, 25, 50, 75 and 100 mg of micafungin daily. Response was evaluated clinically and endoscopically. Results : The protocol defined minimum effective dose of micafungin was 12.5 mg. The percentage of patients experiencing clearing of physical signs and symptoms showed a dose–response relationship and reached 94.7% in the 100 mg dose group. All patients in the 50, 75 and 100 mg dose groups achieved an endoscopically verified improvement in oesophagitis. Adverse effects of micafungin were generally mild and not dose-related. No serious renal, hepatic or drug-related infusion reactions were encountered. Conclusion : Micafungin was found to be effective, well-tolerated and safe. The minimum effective dose was found to be 12.5 mg and a significant linear trend in the successful treatment of oesophageal candidiasis was observed across the doses used with 75 and 100 mg dose levels achieving high rates of clinical and endoscopic cure.
K Pettengell - One of the best experts on this subject based on the ideXlab platform.
-
successful treatment of oesophageal candidiasis by micafungin a novel Systemic Antifungal Agent
Alimentary Pharmacology & Therapeutics, 2004Co-Authors: K Pettengell, J Mynhardt, T Kluyts, D Facklam, D BuellAbstract:Summary Aim : To determine the minimum effective dose and safety of micafungin in the treatment of HIV-related oesophageal candidiasis. Method : A total of 120 patients were enrolled in this open label study of the effects of daily 1 h infusions of micafungin on endoscopically proven fungal oesophagitis. Patients were randomly assigned to receive 12.5, 25, 50, 75 and 100 mg of micafungin daily. Response was evaluated clinically and endoscopically. Results : The protocol defined minimum effective dose of micafungin was 12.5 mg. The percentage of patients experiencing clearing of physical signs and symptoms showed a dose–response relationship and reached 94.7% in the 100 mg dose group. All patients in the 50, 75 and 100 mg dose groups achieved an endoscopically verified improvement in oesophagitis. Adverse effects of micafungin were generally mild and not dose-related. No serious renal, hepatic or drug-related infusion reactions were encountered. Conclusion : Micafungin was found to be effective, well-tolerated and safe. The minimum effective dose was found to be 12.5 mg and a significant linear trend in the successful treatment of oesophageal candidiasis was observed across the doses used with 75 and 100 mg dose levels achieving high rates of clinical and endoscopic cure.
J Mynhardt - One of the best experts on this subject based on the ideXlab platform.
-
successful treatment of oesophageal candidiasis by micafungin a novel Systemic Antifungal Agent
Alimentary Pharmacology & Therapeutics, 2004Co-Authors: K Pettengell, J Mynhardt, T Kluyts, D Facklam, D BuellAbstract:Summary Aim : To determine the minimum effective dose and safety of micafungin in the treatment of HIV-related oesophageal candidiasis. Method : A total of 120 patients were enrolled in this open label study of the effects of daily 1 h infusions of micafungin on endoscopically proven fungal oesophagitis. Patients were randomly assigned to receive 12.5, 25, 50, 75 and 100 mg of micafungin daily. Response was evaluated clinically and endoscopically. Results : The protocol defined minimum effective dose of micafungin was 12.5 mg. The percentage of patients experiencing clearing of physical signs and symptoms showed a dose–response relationship and reached 94.7% in the 100 mg dose group. All patients in the 50, 75 and 100 mg dose groups achieved an endoscopically verified improvement in oesophagitis. Adverse effects of micafungin were generally mild and not dose-related. No serious renal, hepatic or drug-related infusion reactions were encountered. Conclusion : Micafungin was found to be effective, well-tolerated and safe. The minimum effective dose was found to be 12.5 mg and a significant linear trend in the successful treatment of oesophageal candidiasis was observed across the doses used with 75 and 100 mg dose levels achieving high rates of clinical and endoscopic cure.
T Kluyts - One of the best experts on this subject based on the ideXlab platform.
-
successful treatment of oesophageal candidiasis by micafungin a novel Systemic Antifungal Agent
Alimentary Pharmacology & Therapeutics, 2004Co-Authors: K Pettengell, J Mynhardt, T Kluyts, D Facklam, D BuellAbstract:Summary Aim : To determine the minimum effective dose and safety of micafungin in the treatment of HIV-related oesophageal candidiasis. Method : A total of 120 patients were enrolled in this open label study of the effects of daily 1 h infusions of micafungin on endoscopically proven fungal oesophagitis. Patients were randomly assigned to receive 12.5, 25, 50, 75 and 100 mg of micafungin daily. Response was evaluated clinically and endoscopically. Results : The protocol defined minimum effective dose of micafungin was 12.5 mg. The percentage of patients experiencing clearing of physical signs and symptoms showed a dose–response relationship and reached 94.7% in the 100 mg dose group. All patients in the 50, 75 and 100 mg dose groups achieved an endoscopically verified improvement in oesophagitis. Adverse effects of micafungin were generally mild and not dose-related. No serious renal, hepatic or drug-related infusion reactions were encountered. Conclusion : Micafungin was found to be effective, well-tolerated and safe. The minimum effective dose was found to be 12.5 mg and a significant linear trend in the successful treatment of oesophageal candidiasis was observed across the doses used with 75 and 100 mg dose levels achieving high rates of clinical and endoscopic cure.
